GlassScriptPhysician profile
Hart B Moss
NPI 1437393675
$2,788.48
in general payments reported to CMS, 2019-2025
20 companies · $860 in 2025
The $860 reported for 2025 was more than what a typical Cornea and External Diseases Specialist provider received nationally (typical 2025 total: $477).
See the full distribution for Cornea and External Diseases Specialist
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $86.35 · 2020: $213 · 2021: $307 · 2022: $540 · 2023: $459 · 2024: $323 · 2025: $860.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,603 · Honoraria: $38.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,602.93 |
| Honoraria | $38.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $550.97 | 2019-2025 | Istent Inject Trabecular Micro-Bypass System Model G2-M-Is, Iaccess Precision Blade, Ce-Marked Kxla System |
| Alcon Vision LLC | $539.44 | 2020-2025 | Clareon, Hydrus Microstent |
| Rxsight INC | $484.16 | 2023-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
| Ocular Therapeutix, INC. | $259.69 | 2022-2025 | Dextenza |
| New World Medical,INC. | $195.02 | 2023-2025 | Streamline, Clearpath, Kahook Dual Blade |
| Allergan, INC. | $159.78 | 2019-2021 | |
| Dompe US, INC. | $97.62 | 2021-2025 | Oxervate |
| Bausch & Lomb Americas INC. | $91.64 | 2022-2025 | Vyzulta, Envista Envy Iol, Envista Mx60 Iol |
| Kala Pharmaceuticals, INC. | $79.98 | 2021-2022 | |
| Abbvie INC. | $59.37 | 2023-2024 | |
| Rayner Intraocular Lenses Limited | $58.65 | 2022-2023 | Omidria, Rayone Spheric, Rayone Emv |
| The Cameron-Ehlen Group, INC. | $47.08 | 2019 | |
| Novartis Pharmaceuticals Corporation | $40.10 | 2020-2021 | |
| Harrow Eye, LLC | $23.00 | 2024 | Vevye |
| Tarsus Pharmaceuticals, INC. | $22.40 | 2024 | Xdemvy |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $20.55 | 2024 | Ryzumvi, Tyrvaya |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Sight Sciences, INC. | $16.25 | 2021 | |
| Horizon Therapeutics Plc | $14.25 | 2021 | |
| Biotissue Holdings INC. | $9.13 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hart Moss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.